Marchioni, M. Et Al. 2022. Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?. EUROPEAN UROLOGY OPEN SCIENCE , vol.46 , 39-42.

Marchioni, M., Amparore, D., Marandino, L., Bertolo, R., Erdem, S., Ingels, A., ... Muselaers, S.(2022). Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?. EUROPEAN UROLOGY OPEN SCIENCE , vol.46, 39-42.

Marchioni, Michele Et Al. "Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?," EUROPEAN UROLOGY OPEN SCIENCE , vol.46, 39-42, 2022

Marchioni, Michele Et Al. "Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?." EUROPEAN UROLOGY OPEN SCIENCE , vol.46, pp.39-42, 2022

Marchioni, M. Et Al. (2022) . "Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?." EUROPEAN UROLOGY OPEN SCIENCE , vol.46, pp.39-42.

@article{article, author={Michele Marchioni Et Al. }, title={Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?}, journal={EUROPEAN UROLOGY OPEN SCIENCE}, year=2022, pages={39-42} }